Vertex’s VX993 Phase II Setback

The federal government slows progress on mRNA vaccine research. UnitedHealth Group and Amedisys resolve a key legal challenge, clearing the way for their multibillion-dollar merger. And Vertex Pharmaceuticals experiences a delay in its development of a new class of non-opioid pain therapies. Those stories on today’s episode of the Gist Healthcare Podcast.

---

Hosted on Acast. See acast.com/privacy for more information.